The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma.
The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma.
复制标题
DOI：
10.14694/edbk_175230
复制
发表时间：
2017-01-01
期刊：
影响因子：
--
通讯作者：
El-Khoueiry, Anthony
中科院分区：
文献类型：
--
作者：
El-Khoueiry, Anthony
晚期肝细胞癌（HCC）已经提出了一个治疗挑战。尽管其异质性部分与其各种病因有关，但它经常出现在慢性炎症的背景下，这使其成为免疫治疗方法的潜在优秀候选者。有证据表明，HCC中存在抗肿瘤免疫，表现为细胞浸润及其与预后的关系，肿瘤相关抗原的存在，以及免疫介导的自发消退的报道。然而，肝脏本身和肿瘤环境都具有多种抑制抗肿瘤免疫的机制。在这里，我们描述了HCC免疫治疗的基本原理，并讨论了各种免疫治疗方法的新临床数据，包括检查点抑制、细胞治疗、溶瘤病毒治疗和各种组合方法。我们还强调了在疾病的不同阶段适应各种模式的潜力。
Advanced hepatocellular carcinoma (HCC) has presented a therapeutic challenge. Despite its heterogeneity, which is partially related to its various etiologies, it frequently arises in a background of chronic inflammation, which makes it a potentially excellent candidate for immunotherapeutic approaches. There is evidence of antitumor immunity in HCC as manifested by the cell infiltrate and its association with prognosis, the presence of tumor-associated antigens, and the reports of immune-mediated spontaneous regressions. However, both the liver itself and the tumor environment possess a diverse armamentarium of mechanisms that suppress antitumor immunity. Here, we describe the rationale for immunotherapy in HCC and discuss the emerging clinical data from various immunotherapeutic approaches including checkpoint inhibition, cell therapy, oncolytic viral therapy, and various combinatorial approaches. We also highlight the potential for various modalities to be adapted across different stages of the disease.